Jim Mellon [via YouTube]

Health­i­er, longer lifes­pans will be a re­al­i­ty soon­er than you think, Ju­ve­nes­cence promis­es as it clos­es $100M round

Ear­li­er this year, an ex­ec­u­tive from Ju­ve­nes­cence-backed AgeX pre­dict­ed the field of longevi­ty will even­tu­al­ly “dwarf the dot­com boom.” Greg Bai­ley, the UK-based an­ti-ag­ing biotech’s CEO, cer­tain­ly hopes so.

Gre­go­ry Bai­ley

On Mon­day, Ju­ve­nes­cence com­plet­ed its $100 mil­lion Se­ries B round of fi­nanc­ing. The com­pa­ny is backed by British bil­lion­aire Jim Mel­lon — who wrote his 400-page guide to in­vest­ing in the field of longevi­ty short­ly af­ter launch­ing the com­pa­ny in 2017. Bai­ley, who served as a board di­rec­tor for sev­en years at Medi­va­tion be­fore Pfiz­er swal­lowed the biotech for $14 bil­lion, is joined by De­clan Doogan, an in­dus­try vet­er­an with stints at Pfiz­er $PFE and Amarin $AM­RN.

The busi­ness of an­ti-ag­ing is gain­ing steam — Bank of Amer­i­ca has fore­cast the mar­ket will bal­loon to $610 bil­lion by 2025, from an es­ti­mat­ed $110 bil­lion cur­rent­ly — but in­vestors are cau­tious, Bai­ley not­ed in an in­ter­view with End­points News.

“I think there’s a huge amount of skep­ti­cism. There’s an enor­mous num­ber of char­la­tans…I un­der­stand why they would be think­ing you know, is this re­al?” he said. “(W)alk in­to your lo­cal drug­store, you’re go­ing to see about 50 prod­ucts that claim to be an­ti-ag­ing, and I can as­sure you that none of them are. So I think that there’s a healthy dose of skep­ti­cism.”

In­sti­tu­tions tend to move in lock­step when they’re in­vest­ing, he added.

“VCs are as­ton­ish­ing, you know, if one of them buys the yel­low hal­ter top, all of them have to buy a yel­low hal­ter top,” he said, quot­ing tech VC Tim Drap­er.

Bai­ley sug­gest­ed that in­vestors are not quite as en­thu­si­as­tic about plac­ing bets on an­ti-ag­ing, as they are in the tech world. “We’re dra­mat­i­cal­ly be­ing un­der­served…it’s not get­ting the ex­po­sure that tech gets, con­sid­er­ing the size of the mar­ket,” he said. “There is a dis­con­nect on what in­vestors — so­phis­ti­cat­ed in­vestors —  in­sti­tu­tions, how they’re view­ing this, I don’t think they quite grasp how fast this is go­ing to hap­pen, and how big it’s go­ing to be.”

Ju­ve­nes­cence has now raised $165 mil­lion in the last 18 months — in Jan­u­ary it un­veiled the first $46 mil­lion tranche of the Se­ries B — and the mon­ey is be­ing used to fund longevi­ty projects with the lofty goal of ex­tend­ing hu­man lifes­pans to 150 years.

It is a pop­u­lar vi­sion. In­spired by Mel­lon, ven­ture cap­i­tal­ist Sergey Young — who is in charge of all things longevi­ty at the non-prof­it XPRIZE and VC fund BOLD Cap­i­tal Part­ners — un­veiled a $100 mil­lion fund with the same goal in Feb­ru­ary. Google-owned stealthy biotech Cal­i­co is af­ter the same prize — and has part­nered with Ab­b­Vie $AB­BV.

Ju­ve­nes­cence has been busy, col­lab­o­rat­ing with dif­fer­ent groups and set­ting up JVs, such as Alex Zha­voronkov’s AI shop at In­sil­i­co Med­i­cine — and has in­vest­ed in firms in­clud­ing AgeX $AGE and Ly­Ge­n­e­sis. In Feb­ru­ary, Ju­ve­nes­cence de­buted an an­ti-ag­ing joint ven­ture with the Buck In­sti­tute ded­i­cat­ed to in­duc­ing ke­to­sis. In re­cent months, it spawned a new biotech called Sou­vien Ther­a­peu­tics, which is de­vel­op­ing med­i­cines to ad­dress the epi­ge­net­ic un­der­pin­nings of neu­rode­gen­er­a­tive dis­eases, and in­ject­ed $6.5 mil­lion in eq­ui­ty fi­nanc­ing in­to a pre­clin­i­cal meta­bol­ic dis­ease biotech dubbed BY­OMass.

This quar­ter, Ju­ve­nes­cence plans to close three more projects, Bai­ley said. The com­pa­ny is work­ing on for­ti­fy­ing its ma­chine learn­ing ca­pa­bil­i­ty to make sense of huge swathes of da­ta that could help iso­late path­ways to de­vel­op dis­ease-mod­i­fy­ing ther­a­peu­tics, as well as adding prod­ucts to pad its port­fo­lio. The idea is to pur­sue prod­ucts that ad­dress in­flam­ma­tion and fi­bro­sis to slow ag­ing.

Mean­while, the com­pa­ny will main­tain a fo­cus on re­gen­er­a­tion. “I’m mind­ful that if you live to 150, you know, peo­ple don’t want to be all wrin­kled, and in a wheel­chair. So what we want to be able to do is re­gen­er­ate tis­sues,” Bai­ley said.

The plan for an IPO re­mains in place. Yet Bai­ley ac­knowl­edged the com­pa­ny is wary of leap­ing on­to a mar­ket pre­ma­ture­ly, draw­ing a com­par­i­son with plant-based meat sub­sti­tute mak­er Be­yond Meat.

“Clear­ly, we need to have a re­cep­tive mar­ket and…we’ve seen that with Be­yond Meat…so I think that in­vestors are go­ing to come to terms for this in the near fu­ture,” he said. “We’re talk­ing to banks…I think that we’re well-poised, go­ing in­to the next year to do that.”

In the com­ing five to sev­en years, Ju­ve­nes­cence has bold plans. It ex­pects to have at least four an­ti-ag­ing prod­ucts on the mar­ket, Bai­ley said. “I’m hope­ful that we have gone through proof-of-con­cept with three phar­ma­ceu­ti­cal agents and are li­cens­ing with big phar­ma, be­cause we’re not hir­ing 10,000 sales reps. So we’ll let them do that.”

Sci­ence fic­tion is now sci­ence, he un­der­scored. “I think the world is go­ing to be shocked.”

Tesla and SpaceX founder Elon Musk gestures to the audience after being recognized by President Trump following the successful launch of a Falcon 9 rocket at the Kennedy Space Center. (via Getty Images)

Tes­la chief Elon Musk teams up with Covid-19 play­er Cure­Vac to build 'R­NA mi­cro­fac­to­ries'

Elon Musk has joined the global tech crusade now underway to revolutionize vaccine manufacturing — now aimed at delivering billions of doses of a new mRNA vaccine to fight Covid-19. And he’s cutting right to the front.

In a late-night tweet Wednesday, the Tesla chief announced:

Tesla, as a side project, is building RNA microfactories for CureVac & possibly others.

That’s not a lot to go on. But the tweet comes a year after Tesla’s German division in Grohmann and CureVac filed a patent on a “bioreactor for RNA in vitro transcription, a method for RNA in vitro transcription, a module for transcribing DNA into RNA and an automated apparatus for RNA manufacturing.” CureVac, in the meantime, has discussed a variety of plans to build microfactories that can speed up the whole process for a global supply chain.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

George Yancopoulos (Regeneron)

UP­DAT­ED: Re­gen­eron co-founder George Yan­copou­los of­fers a com­bat­ive de­fense of the po­lice at a high school com­mence­ment. It didn’t go well

Typically, the commencement speech at Yorktown Central School District in Westchester — like most high schools — is an opportunity to encourage students to face the future with confidence and hope. Regeneron president and co-founder George Yancopoulos, though, went a different route.

In a fiery speech, the outspoken billionaire defended the police against the “prejudice and bias against law enforcement” that has erupted around the country in street protests from coast to coast. And for many who attended the commencement, Yancopoulos struck the wrong note at the wrong time, especially when he combatively challenged someone for interrupting his speech with a honk for “another act of cowardness.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Elias Zerhouni (Photo by Vincent Isore/IP3/Getty Images)

Elias Zer­houni dis­cuss­es ‘am­a­teur hour’ in DC, the de­struc­tion of in­fec­tious dis­ease R&D and how we need to prep for the next time

Elias Zerhouni favors blunt talk, and in a recent discussion with NPR, the ex-Sanofi R&D and ex-NIH chief had some tough points to make regarding the pandemic response.

Rather than interpret them, I thought it would be best to provide snippets straight from the interview.

On the Trump administration response:

It was basically amateur hour. There is no central concept of operations for preparedness, for pandemics, period. This administration doesn’t want to or has no concept of what it takes to protect the American people and the world because it is codependent. You can’t close your borders and say, “OK, we’re going to be safe.” You’re not going to be able to do that in this world. So it’s a lack of vision, basically just a lack of understanding, of what it takes to protect the American people.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Sec­ond death trig­gers hold on Astel­las' $3B gene ther­a­py biotech's lead pro­gram, rais­ing fresh con­cerns about AAV

Seven months after Astellas shelled out $3 billion to acquire the gene therapy player Audentes, the biotech company’s lead program has been put on hold following the death of 2 patients taking a high dose of their treatment. And there was another serious adverse event recorded in the study as well, with a total of 3 “older” patients in the study affected.

The incidents are derailing plans to file for a near-term approval, which had been expected right about now.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Douglas Love, Annexon CEO (Annexon)

IPO bound? A Bay Area biotech grabs a mega-round on the road to a piv­otal neu­rode­gen­er­a­tion pro­gram

South San Francisco-based Annexon has added $100 million to its cash reserves, along with a new roster of marquee investors backing their play on the classical complement pathway involved in neurodegeneration. And that may well fit the profile for an IPO — though right now everything seems to be working on that score.

Eighteen months after Bain and their syndicate partners put up $75 million to fuel clinical work, Annexon is back at the trough. And this time they’re adding Redmile Group for the lead role, with supporting investments from these new arrivals: BlackRock, Deerfield Management Company, Eventide Asset Management, Farallon Capital Management, Janus Henderson Investors and Logos Capital.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Pfiz­er shares surge on pos­i­tive im­pact of their mR­NA Covid-19 vac­cine — part­nered with BioN­Tech — in an ear­ly-stage study

Pfizer and their partners at the mRNA specialist BioNTech have published the first glimpse of biomarker data from an early-stage study spotlighting the “robust immunogenicity” triggered by their Covid-19 vaccine, which is one of the leaders in the race to vanquish the global pandemic.

Researchers selected 45 healthy volunteers 18-55 years of age for the study. They were randomized to receive 2 doses, separated by 21 days, of 10 µg, 30 µg, or 100 µg of BNT162b1, “a lipid nanoparticle-formulated, nucleoside-modified, mRNA vaccine that encodes trimerized SARS-CoV-2 spike glycoprotein RBD.” Their responses were compared against the effect of a natural, presumably protective defense offered by a regular infection.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Randy Schatzman, Bolt CEO (Bolt Biotherapeutics)

Bolt Bio­ther­a­peu­tics nabs $93.5M to push Provenge in­ven­tor's new idea deep­er in the clin­ic

A cancer-fighting concept from the inventor of the first cancer vaccine is nearing prime time, and its biotech developer has received a significant new infusion of cash to get it there.

Bolt Biotherapeutics announced a $93.5 million Series C round led by Sofinnova Investments and joined by more than 9 others, including Pfizer Ventures and RA Capital Management. That money will go toward pushing the San Francisco biotech’s platform of innate immune-boosting warheads through its first trial on metastatic solid tumors and into several more.

Josh Cohen, Justin Klee

Armed with pos­i­tive ALS da­ta, Amy­lyx scores $30M in fresh fund­ing to com­plete Alzheimer's PhII

Four years after announcing themselves to the biotech world with a new idea for drugging neurodegeneration, backing by the late Henri Termeer and $5 million from Morningside Venture, the young entrepreneurs at Amylyx are back for round 2.

Morningside continued to lead the $30 million Series B, with participation from Termeer’s widow, Belinda, and other unnamed investors. Having celebrated a topline Phase II win for its lead program in amyotrophic lateral sclerosis, Amylyx expects the cash to fund talks with regulators as well as a separate trial for the same drug in Alzheimer’s — for which they had just finished enrolling.

An ex­pe­ri­enced biotech is stitched to­geth­er from transpa­cif­ic parts, with 265 staffers and a fo­cus on ‘new bi­ol­o­gy’

Over the past few years, different teams at a pair of US-based biotechs and in labs in Japan have labored to piece together a group of cancer drug programs, sharing a single corporate umbrella with research colleagues in Japan. But now their far-flung operations have been knit together into a single unit, creating a pipeline with 10 cancer drug development programs — going from early-stage right into Phase III — and a host of discovery projects managed by a collective staff of some 265 people.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.